Topical Curcumin for Prevention of Radiation-Induced Dermatitis: A Pilot Double‑Blind, Placebo‑Controlled Trial.

IF 1.8 4区 医学 Q3 ONCOLOGY
Cancer Investigation Pub Date : 2025-03-01 Epub Date: 2025-03-27 DOI:10.1080/07357907.2025.2479542
Behrooz Heydari, Soudabe Sheikhalishahi, Farahnaz Hoseinzade, Masood Shabani, Vahid Ramezani, Fatemeh Saghafi
{"title":"Topical Curcumin for Prevention of Radiation-Induced Dermatitis: A Pilot Double‑Blind, Placebo‑Controlled Trial.","authors":"Behrooz Heydari, Soudabe Sheikhalishahi, Farahnaz Hoseinzade, Masood Shabani, Vahid Ramezani, Fatemeh Saghafi","doi":"10.1080/07357907.2025.2479542","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Radiation-induced dermatitis, a common radiotherapy (RT) complication, affects 95% of breast cancer patients, with 10% experiencing severe reactions. Despite advancements, radiation dermatitis remains a challenge, disrupting treatment schedules and compromising patients' quality of life. Exploring herbal compounds, particularly Curcumin, has shown promise in addressing radiation-induced dermatitis, with its non-toxic and anti-inflammatory properties offering the potential for clinical trials to prevent these reactions.</p><p><strong>Methods: </strong>This phase II randomized, double-blinded, placebo-controlled trial focused on adult females undergoing conventional fractionated RT. The main objective was to assess the efficacy of topical Curcumin in reducing the severity of radiation dermatitis.</p><p><strong>Results: </strong>During a five-month study, 52 breast cancer patients completed the research. Participants were divided into Curcumin and placebo groups. In the first week, a significant difference in redness (P-value = 0.001) and irritation (P-value = 0.017) was observed, with the Curcumin group showing lower percentages. This trend continued in the second, third, and fourth weeks (P-value = 0.001). No statistical difference was found in itching (P-value = 0.446), and the occurrence of dryness (P-value = 1.000) remained constant in both groups throughout the four weeks. In pain the differences were significant in the second, third, and fourth weeks (P-value = 0.001).</p><p><strong>Conclusion: </strong>The study highlights the success of a 2% Curcumin gel in reducing skin side effects during breast cancer radiation therapy, suggesting its potential to enhance patients' quality of life.</p><p><strong>Trial registration: </strong>IRCT20181208041882N3, 06/11/2020 (https://en.irct.ir/trial/49228).</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"173-182"},"PeriodicalIF":1.8000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/07357907.2025.2479542","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/27 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Radiation-induced dermatitis, a common radiotherapy (RT) complication, affects 95% of breast cancer patients, with 10% experiencing severe reactions. Despite advancements, radiation dermatitis remains a challenge, disrupting treatment schedules and compromising patients' quality of life. Exploring herbal compounds, particularly Curcumin, has shown promise in addressing radiation-induced dermatitis, with its non-toxic and anti-inflammatory properties offering the potential for clinical trials to prevent these reactions.

Methods: This phase II randomized, double-blinded, placebo-controlled trial focused on adult females undergoing conventional fractionated RT. The main objective was to assess the efficacy of topical Curcumin in reducing the severity of radiation dermatitis.

Results: During a five-month study, 52 breast cancer patients completed the research. Participants were divided into Curcumin and placebo groups. In the first week, a significant difference in redness (P-value = 0.001) and irritation (P-value = 0.017) was observed, with the Curcumin group showing lower percentages. This trend continued in the second, third, and fourth weeks (P-value = 0.001). No statistical difference was found in itching (P-value = 0.446), and the occurrence of dryness (P-value = 1.000) remained constant in both groups throughout the four weeks. In pain the differences were significant in the second, third, and fourth weeks (P-value = 0.001).

Conclusion: The study highlights the success of a 2% Curcumin gel in reducing skin side effects during breast cancer radiation therapy, suggesting its potential to enhance patients' quality of life.

Trial registration: IRCT20181208041882N3, 06/11/2020 (https://en.irct.ir/trial/49228).

局部姜黄素预防辐射性皮炎:一项双盲安慰剂对照试验。
背景:放射诱发性皮炎是一种常见的放疗(RT)并发症,95%的乳腺癌患者受到影响,其中10%出现严重反应。尽管取得了进展,但放射性皮炎仍然是一个挑战,它扰乱了治疗计划,损害了患者的生活质量。探索草药化合物,特别是姜黄素,在解决辐射性皮炎方面显示出希望,其无毒和抗炎特性为临床试验提供了预防这些反应的潜力。方法:这项II期随机、双盲、安慰剂对照试验主要针对接受常规分步放射治疗的成年女性。主要目的是评估局部姜黄素降低放射性皮炎严重程度的疗效。结果:在为期五个月的研究中,52名乳腺癌患者完成了研究。参与者被分为姜黄素组和安慰剂组。在第一周,观察到发红(p值= 0.001)和刺激(p值= 0.017)有显著差异,姜黄素组的百分比较低。这一趋势在第二、第三和第四周持续(p值= 0.001)。两组在瘙痒方面无统计学差异(p值= 0.446),在四周内,两组的干燥发生率保持不变(p值= 1.000)。在疼痛方面,第2、3、4周差异显著(p值= 0.001)。结论:该研究强调了2%姜黄素凝胶在减少乳腺癌放射治疗期间皮肤副作用方面的成功,这表明它有可能提高患者的生活质量。试验注册:IRCT20181208041882N3, 06/11/2020 (https://en.irct.ir/trial/49228)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Investigation
Cancer Investigation 医学-肿瘤学
CiteScore
3.80
自引率
4.20%
发文量
71
审稿时长
8.5 months
期刊介绍: Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信